Enanta Pharmaceuticals, Inc

NYSE/NASDAQ:ENTAPharma

Watertown, Massachusetts, United States · Est. 1995 · 250 employees

Enanta Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel antiviral therapies for infectious diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

By Therapeutic Area

top 1

Infectious Disease

1100%

R&D Momentum

27/100

Pipeline Velocity

6/100

Trial Completion Rate

90/100

Pipeline Concentration

100/100

Pipeline Freshness

0/100

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Recruiting

Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Earlier

Jun 18, 2026EX-99.2ENANTA PHARMACEUTICALS INC (ENTA) (CIK 0001177648)

Mar 13, 2025TrialA Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Jan 27, 2025TrialA Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Jul 15, 2024TrialA Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Nov 20, 2023TrialA Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Nov 29, 2022TrialA Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Nov 10, 2022TrialA Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

4 more events

Oct 6, 2022TrialDrug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Oct 6, 2022TrialDrug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Sep 29, 2022TrialA Study of EDP-323 in Healthy Subjects